Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 21,046 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Contraception
Interventions: Mirena (levonorgestrel-releasing intrauterine system); Device
Lead sponsor: University of Louisville; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Atrial Fibrillation
Interventions: WHOOP 4.0 Strap, BioTel ePatch; Device
Lead sponsor: Yale University; Other
Eligibility: 22 Years and older
Enrollment: 653 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Usher Syndrome, Retinitis Pigmentosa
Interventions: SAR421869; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 6 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Physical Activity
Interventions: Test of Existing MI Products; Behavioral
Lead sponsor: University of South Carolina; Other
Eligibility: Not listed
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Columbia, South Carolina

Conditions: Type 2 Diabetes
Interventions: dietary fiber, HFHC meal; Dietary Supplement · Other
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions: Beef+; Other
Lead sponsor: Texas A&M University; Other
Eligibility: 11 Years to 17 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Solid Tumors
Interventions: dovitinib, fulvestrant; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Las Vegas, Nevada • The Bronx, New York

Conditions: Stroke, Aphasia
Interventions: Active transcranial direct current stimulation (tDCS), Sham transcranial direct current stimulation (tDCS), Language Specific Attention Treatment; Device · Behavioral
Lead sponsor: Syracuse University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Asthma
Interventions: PIPA Intervention Bundle 1, PIPA Intervention Bundle 2; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD)
Interventions: L-theanine and paraxanthine, Placebo; Dietary Supplement
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Aortic Aneurysm, Abdominal, Carotid Atherosclerosis
Interventions: 18F-FPPRGD2, Positron emission tomography, Computed tomography, Magnetic Resonance Imaging; Drug · Device · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: HIV -1 Infection
Interventions: Live Biotherapeutic Product L. jensenii 1153-1666, Placebo; Drug
Lead sponsor: Craig Cohen, MD, MPH; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Glaucoma
Interventions: Efficacy-patient navigator to improve follow-up adherence, Office-Based Usual Care; Behavioral
Lead sponsor: Wills Eye; Other
Eligibility: 50 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Anxiety, Depression, Post Traumatic Stress Disorder, Satisfaction
Interventions: POST Facilitation, Home Safety Evaluation; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 65 Years and older
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Indianapolis, Indiana

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
Interventions: Trastuzumab deruxtecan, Trastuzumab, Pertuzumab, Endocrine Therapy, Palbociclib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 5
States / cities: Columbia, Maryland • Las Vegas, Nevada • Nashville, Tennessee + 2 more

Conditions: Health Personnel, Stress, Anxiety, Insomnia, Depression
Interventions: Cereset Research; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Neurofibromatosis Type 2, Vestibular Schwannoma, Non-vestibular Schwannoma, Meningioma, Ependymoma
Interventions: Brigatinib, Neratinib, Retifanlimab, Bevacizumab; Drug
Lead sponsor: Scott R. Plotkin, MD, PhD; Other
Eligibility: 12 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 6
States / cities: Los Angeles, California • Miami, Florida • Indianopolis, Indiana + 3 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate HCl ER tablets 1, Placebo, Methylphenidate HCl ER tablets 2, Methylphenidate HCl ER for suspension; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 6 Years to 12 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Boston, Massachusetts • Las Vegas, Nevada

Conditions: Arterial Ischemic Stroke (AIS) in Children
Interventions: Autologous Human Cord Blood derived Stem Cell injection; Biological
Lead sponsor: Aryn Knight; Other
Eligibility: 6 Weeks to 6 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Systematic Acupuncture
Interventions: Acupuncture Treatments; Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 20 Years to 60 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Leg Cramp, Nocturnal
Interventions: Theraworx, Placebo; Device · Other
Lead sponsor: Sport and Spine Rehab Clinical Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Traumatic Injury
Interventions: Caregiver Counseling for Childhood Traumatic Injury, Standard of Care for Childhood Traumatic Injury; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 1 Year to 6 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Short Bowel Syndrome
Interventions: WHO ORS, Commercial ORS; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 90 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer, Survivorship
Interventions: PROMIS-SF v2.0 -Cognitive Function 8a; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 200 participants
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Search by objective public record fields.

Safety and Expulsion of Delayed Versus Immediate Postpartum Intrauterine Device Placement

WHOOP Abnormal Rhythm Notification

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

Classroom Activities

Anti-inflammatory Effects of the Fiber

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective

Improving Aphasia Using Electrical Brain Stimulation

Implementing Pathways to Improve Pediatric Asthma Care

L-theanine and Paraxanthine for Cognitive Improvement in Adults With ADHD and ASD

Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation

Safety Study of MucoCept-CVN

Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population

POST Facilitation for Community Dwelling Older Adults (POST-RCT)

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

Cereset Research for Performance Improvement in a Hospital Nursing Unit

Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)

PK/PD Pediatric ADHD Classroom Study

Umbilical Cord Blood in the Treatment of Stroke in Children.

Acupuncture for Stroke Recovery

Effect of Theraworx/[pH]Uel on Night-time Leg Cramps and Spasm Symptoms

Pediatric and Caregiver Traumatic Stress Intervention (PACTS)

Comparison of Different Oral Rehydration Solutions

A Study of Cognitive Health in Survivors of Prostate Cancer